MEA Acute Myeloid Leukemia Diagnostics Market - Industry Trends and Forecast to 2034

Description

List of Tables

Middle East and Africa Acute Myeloid Leukemia Diagnostics Market is projected to register a substantial CAGR of 7.9% in the forecast period of 2024 to 2031. The new market report contains data for the historic year 2022, the base year of calculation is 2023, and the forecast period is 2024 to 2031.

Market Segmentation

Middle East and Africa Acute Myeloid Leukemia Diagnostics Market, By Product Type (Instruments, and Consumables & Accessories), Test Type (Imaging Test, Blood Test, Bone Marrow Test, Biomarker Test, Immunophenotyping, Genetic Testing and Others), Cancer Type (Myeloblastic (M0), Myeloblastic (M1), Myeloblastic (M2), Promyelocytic (M3), Myelomonocytic (M4), MONOCYTIC (M5), Erythroleukemia (M6) and Megakaryocytic (M7)), Age Group (Below 21, 21-29, 30-65, 65 and Above), Gender (Male and Female) End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country (South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa) - Industry Trends and Forecast to 2031.

Driver

Increasing diagnostic products for leukemia cancer

Restraint

Late diagnosis and Poor prognosis of leukemia

Opportunity

Initiatives by government and other authorities for life sciences and funding

Market Players

Some of the major market players in Middle East and Africa acute myeloid leukemia diagnostics market are:

F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific, Inc.
QIAGEN
Abbott
Siemens Healthcare GmbH
Hologic, Inc.
Agilent Technologies, Inc.
DiaSorin S.p.A.
Illumina, Inc.
BIOMERIEUX

1 INTRODUCTION 52

1.1 OBJECTIVES OF THE STUDY 52
1.2 MARKET DEFINITION 52
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET 52
1.4 LIMITATIONS 54
1.5 MARKETS COVERED 55

2 MARKET SEGMENTATION 58

2.1 MARKETS COVERED 58
2.2 GEOGRAPHICAL SCOPE 59
2.3 YEARS CONSIDERED FOR THE STUDY 60
2.4 CURRENCY AND PRICING 60
2.5 DBMR TRIPOD DATA VALIDATION MODEL 61
2.6 MULTIVARIATE MODELLING 64
2.7 PRODUCT TYPE LIFELINE CURVE 64
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 65
2.9 DBMR MARKET POSITION GRID 66
2.10 MARKET END USER COVERAGE GRID 67
2.11 VENDOR SHARE ANALYSIS 68
2.12 SECONDARY SOURCES 69
2.13 ASSUMPTIONS 69

3 EXECUTIVE SUMMARY 70

4 PREMIUM INSIGHTS 73

4.1 PESTEL ANALYSIS 74
4.2 PORTER'S FIVE FORCES 75
4.3 EPIDEMIOLOGY 76

5 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, REGULATIONS 77

5.1 REGULATORY SCENARIO IN THE U.S. 77
5.2 REGULATORY SCENARIO IN AUSTRALIA 78
5.3 REGULATORY SCENARIO IN JAPAN 78
5.4 REGULATORY SCENARIO IN CHINA 78

6 MARKET OVERVIEW 80

6.1 DRIVERS 82
- 6.1.1 GROWING PREVALENCE OF LEUKEMIA CANCER 82
- 6.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS 84
- 6.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 84
- 6.1.4 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER 85
6.2 RESTRAINTS 85
- 6.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS 85
- 6.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA 86
6.3 OPPORTUNITIES 86
- 6.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA 86
- 6.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 87
- 6.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 88
6.4 CHALLENGES 88
- 6.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 88
- 6.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 89

7 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE 90

7.1 OVERVIEW 91
7.2 INSTRUMENTS 94
- 7.2.1 BIOPSY INSTRUMENTS 95
  - 7.2.1.1 BONE MARROW BIOPSY 95
  - 7.2.1.2 NEEDLE BIOPSY 95
  - 7.2.1.3 SURGICAL BIOPSY 95
  - 7.2.1.4 OTHERS 95
- 7.2.2 PATHOLOGY-BASED INSTRUMENTS 96
  - 7.2.2.1 PCR INSTRUMENTS 96
  - 7.2.2.2 SLIDE STAINING SYSTEMS 96
  - 7.2.2.3 TISSUE PROCESSING SYSTEMS 96
  - 7.2.2.4 CELL PROCESSORS 96
  - 7.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS 96
- 7.2.3 IMAGING INSTRUMENTS 97
  - 7.2.3.1 ULTRASOUND SYSTEMS 97
  - 7.2.3.2 CT SYSTEMS 97
  - 7.2.3.3 MRI SYSTEMS 97
  - 7.2.3.4 OTHERS 97
- 7.2.4 OTHERS 97

7.3 CONSUMABLES & ACCESSORIES 98
- 7.3.1 KITS 99
  - 7.3.1.1 PCR KITS 99
  - 7.3.1.2 DNA POLYMERASE KITS 99
  - 7.3.1.3 NUCLEIC ACID ISOLATION KITS 99
  - 7.3.1.4 OTHERS 99
- 7.3.2 REAGENTS 100
  - 7.3.2.1 ASSAYS 100
  - 7.3.2.2 BUFFERS 100
  - 7.3.2.3 PRIMERS 100
  - 7.3.2.4 OTHERS 100
- 7.3.3 PROBES 101
- 7.3.4 OTHER CONSUMABLES 101

8 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE 102

8.1 OVERVIEW 103
8.2 BLOOD TEST 106
- 8.2.1 COMPLETE BLOOD COUNT (CBC) 107
- 8.2.2 BLOOD CHEMISTRY TESTS 107
- 8.2.3 OTHERS 107
8.3 IMAGING TEST 108
- 8.3.1 COMPUTED TOMOGRAPHY (CT) SCAN 108
- 8.3.2 MRI 108
- 8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 109
- 8.3.4 OTHERS 109
8.4 BONE MARROW TESTS 109
- 8.4.1 BONE MARROW ASPIRATE 110
- 8.4.2 BONE MARROW BIOPSY 110
- 8.4.3 OTHERS 110
8.5 GENETIC TESTS 110
- 8.5.1 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 111
- 8.5.2 KARYOTYPING 111
- 8.5.3 OTHERS 111
8.6 BIOMARKER TEST 112
- 8.6.1 GENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 112
- 8.6.2 EPIGENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 112
- 8.6.3 PROTEOMIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 113

8.7 IMMUNOPHENOTYPING 113
- 8.7.1 FLOW CYTOMETRY 113
- 8.7.2 IMMUNOHISTOCHEMISTRY 114
- 8.7.3 OTHERS 114
8.8 OTHERS 114

9 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE 115

9.1 OVERVIEW 116
9.2 MYELOBLASTIC (M0) 119
9.3 MYELOBLASTIC (M1) 120
9.4 MYELOBLASTIC (M2) 120
9.5 PROMYELOCYTIC (M3) 121
9.6 MYELOMONOCYTIC (M4) 121
9.7 MONOCYTIC (M5) 122
9.8 ERYTHROLEUKEMIA (M6) 122
9.9 MEGAKARYOCYTIC (M7) 123

10 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP 124

10.1 OVERVIEW 125
10.2 65 AND ABOVE 128
10.3 30-65 129
10.4 BELOW 21 129
10.5 21-29 130

11 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER 131

11.1 OVERVIEW 132
11.2 MALE 135
11.3 FEMALE 136

12 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER 137

12.1 OVERVIEW 138
12.2 HOSPITALS 141
12.3 ASSOCIATED LABS 142
12.4 INDEPENDENT DIAGNOSTIC LABORATORIES 142
12.5 DIAGNOSTIC IMAGING CENTERS 143
12.6 CANCER RESEARCH INSTITUTES 143
12.7 OTHERS 144

13 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 145

13.1 OVERVIEW 146
13.2 DIRECT TENDER 149
13.3 RETAIL SALES 150

14 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION 151

14.1 MIDDLE EAST AND AFRICA 154
- 14.1.1 SOUTH AFRICA 160
- 14.1.2 SAUDI ARABIA 165
- 14.1.3 U.A.E 170
- 14.1.4 EGYPT 175
- 14.1.5 ISRAEL 180
- 14.1.6 REST OF MIDDLE EAST AND AFRICA 185

15 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 186

15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 186

16 SWOT ANALYSIS 187

17 COMPANY PROFILES 188

17.1 CANON MEDICAL SYSTEMS CORPORATION. 188
- 17.1.1 COMPANY SNAPSHOT 188
- 17.1.2 REVENUE ANALYSIS 189
- 17.1.3 COMPANY SHARE ANALYSIS 189
- 17.1.4 PRODUCT PORTFOLIO 190
- 17.1.5 RECENT DEVELOPMENT 190
17.2 SYSMEX CORPORATION 191
- 17.2.1 COMPANY SNAPSHOT 191
- 17.2.2 REVENUE ANALYSIS 191
- 17.2.3 COMPANY SHARE ANALYSIS 192
- 17.2.4 PRODUCT PORTFOLIO 192
- 17.2.5 RECENT DEVELOPMENT 192

17.3 EPIGENOMICS AG. 193
- 17.3.1 COMPANY SNAPSHOT 193
- 17.3.2 REVENUE ANALYSIS 193
- 17.3.3 COMPANY SHARE ANALYSIS 194
- 17.3.4 PRODUCT PORTFOLIO 194
- 17.3.5 RECENT DEVELOPMENT 195
17.4 MYRIAD GENETICS, INC. 196
- 17.4.1 COMPANY SNAPSHOT 196
- 17.4.2 REVENUE ANALYSIS 196
- 17.4.3 COMPANY SHARE ANALYSIS 197
- 17.4.4 PRODUCT PORTFOLIO 197
- 17.4.5 RECENT DEVELOPMENT 198
17.5 F. HOFFMANN- LA ROCHE LTD 199
- 17.5.1 COMPANY SNAPSHOT 199
- 17.5.2 REVENUE ANALYSIS 199
- 17.5.3 COMPANY SHARE ANALYSIS 200
- 17.5.4 PRODUCT PORTFOLIO 200
- 17.5.5 RECENT DEVELOPMENT 200
17.6 ABBOTT 201
- 17.6.1 COMPANY SNAPSHOT 201
- 17.6.2 REVENUE ANALYSIS 201
- 17.6.3 PRODUCT PORTFOLIO 202
- 17.6.4 RECENT DEVELOPMENT 202
17.7 AGILENT TECHNOLOGIES, INC. 203
- 17.7.1 COMPANY SNAPSHOT 203
- 17.7.2 REVENUE ANALYSIS 203
- 17.7.3 PRODUCT PORTFOLIO 204
- 17.7.4 RECENT DEVELOPMENT 204
17.8 BD 205
- 17.8.1 COMPANY SNAPSHOT 205
- 17.8.2 REVENUE ANALYSIS 205
- 17.8.3 PRODUCT PORTFOLIO 206
- 17.8.4 RECENT DEVELOPMENT 206
17.9 BIOMERIEUX 207
- 17.9.1 COMPANY SNAPSHOT 207
- 17.9.2 PRODUCT PORTFOLIO 207
- 17.9.3 RECENT DEVELOPMENT 207

17.10 BIO-RAD LABORATORIES, INC. 208
- 17.10.1 COMPANY SNAPSHOT 208
- 17.10.2 REVENUE ANALYSIS 208
- 17.10.3 PRODUCT PORTFOLIO 209
- 17.10.4 RECENT DEVELOPMENT 209
17.11 DIASORIN S.P.A. 210
- 17.11.1 COMPANY SNAPSHOT 210
- 17.11.2 REVENUE ANALYSIS 210
- 17.11.3 PRODUCT PORTFOLIO 211
- 17.11.4 RECENT DEVELOPMENTS 211
17.12 EXACT SCIENCES CORPORATION 212
- 17.12.1 COMPANY SNAPSHOT 212
- 17.12.2 REVENUE ANALYSIS 212
- 17.12.3 PRODUCT PORTFOLIO 213
- 17.12.4 RECENT DEVELOPMENTS 213
17.13 HOLOGIC INC. 214
- 17.13.1 COMPANY SNAPSHOT 214
- 17.13.2 REVENUE ANALYSIS 214
- 17.13.3 PRODUCT PORTFOLIO 215
- 17.13.4 RECENT DEVELOPMENT 215
17.14 ILLUMINA, INC. 216
- 17.14.1 COMPANY SNAPSHOT 216
- 17.14.2 REVENUE ANALYSIS 216
- 17.14.3 PRODUCT PORTFOLIO 217
- 17.14.4 RECENT DEVELOPMENT 217
17.15 KONINKLIJKE PHILIPS N.V. 218
- 17.15.1 COMPANY SNAPSHOT 218
- 17.15.2 REVENUE ANALYSIS 218
- 17.15.3 PRODUCT PORTFOLIO 219
- 17.15.4 RECENT DEVELOPMENT 219
17.16 MEDONICA CO. LTD 220
- 17.16.1 COMPANY SNAPSHOT 220
- 17.16.2 PRODUCT PORTFOLIO 220
- 17.16.3 RECENT DEVELOPMENT 220
17.17 MINFOUND MEDICAL SYSTEMS CO., LTD 221
- 17.17.1 COMPANY SNAPSHOT 221
- 17.17.2 PRODUCT PORTFOLIO 221
- 17.17.3 RECENT DEVELOPMENT 222
17.18 PLEXBIO 223
- 17.18.1 COMPANY SNAPSHOT 223
- 17.18.2 PRODUCT PORTFOLIO 223
- 17.18.3 RECENT DEVELOPMENTS 223
17.19 QIAGEN 224
- 17.19.1 COMPANY SNAPSHOT 224
- 17.19.2 REVENUE ANALYSIS 224
- 17.19.3 PRODUCT PORTFOLIO 225
- 17.19.4 RECENT DEVELOPMENTS 225
17.20 QUEST DIAGNOSTICS INCORPORATED 226
- 17.20.1 COMPANY SNAPSHOT 226
- 17.20.2 REVENUE ANALYSIS 226
- 17.20.3 PRODUCT PORTFOLIO 227
- 17.20.4 RECENT DEVELOPMENTS 227
17.21 SIEMENS HEALTHCARE GMBH 228
- 17.21.1 COMPANY SNAPSHOT 228
- 17.21.2 REVENUE ANALYSIS 228
- 17.21.3 PRODUCT PORTFOLIO 229
- 17.21.4 RECENT DEVELOPMENT 229
17.22 SONIC HEALTHCARE 230
- 17.22.1 COMPANY SNAPSHOT 230
- 17.22.2 PRODUCT PORTFOLIO 230
- 17.22.3 RECENT DEVELOPMENT 230
17.23 STERNMED GMBH 231
- 17.23.1 COMPANY SNAPSHOT 231
- 17.23.2 PRODUCT PORTFOLIO 231
- 17.23.3 RECENT DEVELOPMENTS 231
17.24 THERMO FISHER SCIENTIFIC INC. 232
- 17.24.1 COMPANY SNAPSHOT 232
- 17.24.2 REVENUE ANALYSIS 232
- 17.24.3 PRODUCT PORTFOLIO 233
- 17.24.4 RECENT DEVELOPMENT 233
17.25 TIME MEDICAL HOLDING 234
- 17.25.1 COMPANY SNAPSHOT 234
- 17.25.2 PRODUCT PORTFOLIO 234
- 17.25.3 RECENT DEVELOPMENT 235

18 QUESTIONNAIRE 236

19 RELATED REPORTS 240

LIST OF TABLES

TABLE 1 APPROVED DIAGNOSTICS OF LEUKEMIA 58
TABLE 2 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 65
TABLE 3 MIDDLE EAST AND AFRICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 65
TABLE 4 MIDDLE EAST AND AFRICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 65
TABLE 5 MIDDLE EAST AND AFRICA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 66
TABLE 6 MIDDLE EAST AND AFRICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 67
TABLE 7 MIDDLE EAST AND AFRICA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 68
TABLE 8 MIDDLE EAST AND AFRICA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 69
TABLE 9 MIDDLE EAST AND AFRICA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 69
TABLE 10 MIDDLE EAST AND AFRICA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 70
TABLE 11 MIDDLE EAST AND AFRICA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 71
TABLE 12 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 77
TABLE 13 MIDDLE EAST AND AFRICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 77
TABLE 14 MIDDLE EAST AND AFRICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 78
TABLE 15 MIDDLE EAST AND AFRICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 79
TABLE 16 MIDDLE EAST AND AFRICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 79
TABLE 17 MIDDLE EAST AND AFRICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 80
TABLE 18 MIDDLE EAST AND AFRICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 80
TABLE 19 MIDDLE EAST AND AFRICA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 81
TABLE 20 MIDDLE EAST AND AFRICA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 82
TABLE 21 MIDDLE EAST AND AFRICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 83
TABLE 22 MIDDLE EAST AND AFRICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 83
TABLE 23 MIDDLE EAST AND AFRICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 84
TABLE 24 MIDDLE EAST AND AFRICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 84
TABLE 25 MIDDLE EAST AND AFRICA OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 85
TABLE 26 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 90
TABLE 27 MIDDLE EAST AND AFRICA MYELOBLASTIC (M0) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 90
TABLE 28 MIDDLE EAST AND AFRICA MYELOBLASTIC (M1) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 91
TABLE 29 MIDDLE EAST AND AFRICA MYELOBLASTIC (M2) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 91
TABLE 30 MIDDLE EAST AND AFRICA PROMYELOCYTIC (M3) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 92
TABLE 31 MIDDLE EAST AND AFRICA MYELOMONOCYTIC (M4) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 92
TABLE 32 MIDDLE EAST AND AFRICA MONOCYTIC (M5) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 93
TABLE 33 MIDDLE EAST AND AFRICA ERYTHROLEUKEMIA (M6) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 93
TABLE 34 MIDDLE EAST AND AFRICA MEGAKARYOCYTIC (M7) ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 94
TABLE 35 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 99
TABLE 36 MIDDLE EAST AND AFRICA 65 AND ABOVE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 99
TABLE 37 MIDDLE EAST AND AFRICA 30-65 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 100
TABLE 38 MIDDLE EAST AND AFRICA BELOW 21 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 100
TABLE 39 MIDDLE EAST AND AFRICA 21-29 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 101
TABLE 40 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 106
TABLE 41 MIDDLE EAST AND AFRICA MALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 106
TABLE 42 MIDDLE EAST AND AFRICA FEMALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 107
TABLE 43 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 112
TABLE 44 MIDDLE EAST AND AFRICA HOSPITALS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 112
TABLE 45 MIDDLE EAST AND AFRICA ASSOCIATED LABS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 113
TABLE 46 MIDDLE EAST AND AFRICA INDEPENDENT DIAGNOSTIC LABORATORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 113
TABLE 47 MIDDLE EAST AND AFRICA DIAGNOSTIC IMAGING CENTERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 114
TABLE 48 MIDDLE EAST AND AFRICA CANCER RESEARCH INSTITUTES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 114
TABLE 49 MIDDLE EAST AND AFRICA OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 115
TABLE 50 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 120
TABLE 51 MIDDLE EAST AND AFRICA DIRECT TENDER IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 120
TABLE 52 MIDDLE EAST AND AFRICA RETAIL SALES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 121
TABLE 53 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY COUNTRY, 2022-2031 (USD MILLION) 125
TABLE 54 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 125
TABLE 55 MIDDLE EAST AND AFRICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 125
TABLE 56 MIDDLE EAST AND AFRICA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 126
TABLE 57 MIDDLE EAST AND AFRICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 126
TABLE 58 MIDDLE EAST AND AFRICA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 126
TABLE 59 MIDDLE EAST AND AFRICA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 126
TABLE 60 MIDDLE EAST AND AFRICA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 127
TABLE 61 MIDDLE EAST AND AFRICA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 127
TABLE 62 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 127
TABLE 63 MIDDLE EAST AND AFRICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 127
TABLE 64 MIDDLE EAST AND AFRICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 128
TABLE 65 MIDDLE EAST AND AFRICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 128
TABLE 66 MIDDLE EAST AND AFRICA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 128
TABLE 67 MIDDLE EAST AND AFRICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 128
TABLE 68 MIDDLE EAST AND AFRICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 129
TABLE 69 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 129
TABLE 70 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 129
TABLE 71 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 129
TABLE 72 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 130
TABLE 73 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 130
TABLE 74 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 131
TABLE 75 SOUTH AFRICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 131
TABLE 76 SOUTH AFRICA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 131
TABLE 77 SOUTH AFRICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 131
TABLE 78 SOUTH AFRICA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 132
TABLE 79 SOUTH AFRICA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 132
TABLE 80 SOUTH AFRICA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 132
TABLE 81 SOUTH AFRICA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 132
TABLE 82 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 133
TABLE 83 SOUTH AFRICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 133
TABLE 84 SOUTH AFRICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 133
TABLE 85 SOUTH AFRICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 133
TABLE 86 SOUTH AFRICA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 134
TABLE 87 SOUTH AFRICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 134
TABLE 88 SOUTH AFRICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 134
TABLE 89 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 134
TABLE 90 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 135
TABLE 91 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 135
TABLE 92 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 135
TABLE 93 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 135
TABLE 94 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 136
TABLE 95 SAUDI ARABIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 136
TABLE 96 SAUDI ARABIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 136
TABLE 97 SAUDI ARABIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 136
TABLE 98 SAUDI ARABIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 137
TABLE 99 SAUDI ARABIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 137
TABLE 100 SAUDI ARABIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 137
TABLE 101 SAUDI ARABIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 137
TABLE 102 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 138
TABLE 103 SAUDI ARABIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 138
TABLE 104 SAUDI ARABIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 138
TABLE 105 SAUDI ARABIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 138
TABLE 106 SAUDI ARABIA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 139
TABLE 107 SAUDI ARABIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 139
TABLE 108 SAUDI ARABIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 139
TABLE 109 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 139
TABLE 110 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 140
TABLE 111 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 140
TABLE 112 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 140
TABLE 113 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 140
TABLE 114 U.A.E. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 141
TABLE 115 U.A.E. INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 141
TABLE 116 U.A.E. BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 141
TABLE 117 U.A.E. PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 141
TABLE 118 U.A.E. IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 142
TABLE 119 U.A.E. CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 142
TABLE 120 U.A.E. KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 142
TABLE 121 U.A.E. REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 142
TABLE 122 U.A.E. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 143
TABLE 123 U.A.E. BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 143
TABLE 124 U.A.E. IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 143
TABLE 125 U.A.E. BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 143
TABLE 126 U.A.E. GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 144
TABLE 127 U.A.E. BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 144
TABLE 128 U.A.E. IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 144
TABLE 129 U.A.E. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 144
TABLE 130 U.A.E. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 145
TABLE 131 U.A.E. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 145
TABLE 132 U.A.E. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 145
TABLE 133 U.A.E. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 145
TABLE 134 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 146
TABLE 135 EGYPT INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 146
TABLE 136 EGYPT BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 146
TABLE 137 EGYPT PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 146
TABLE 138 EGYPT IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 147
TABLE 139 EGYPT CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 147
TABLE 140 EGYPT KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 147
TABLE 141 EGYPT REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 147
TABLE 142 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 148
TABLE 143 EGYPT BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 148
TABLE 144 EGYPT IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 148
TABLE 145 EGYPT BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 148
TABLE 146 EGYPT GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 149
TABLE 147 EGYPT BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 149
TABLE 148 EGYPT IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 149
TABLE 149 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 149
TABLE 150 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 150
TABLE 151 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 150
TABLE 152 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 150
TABLE 153 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 150
TABLE 154 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 151
TABLE 155 ISRAEL INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 151
TABLE 156 ISRAEL BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 151
TABLE 157 ISRAEL PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 151
TABLE 158 ISRAEL IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 152
TABLE 159 ISRAEL CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 152
TABLE 160 ISRAEL KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 152
TABLE 161 ISRAEL REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 152
TABLE 162 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 153
TABLE 163 ISRAEL BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 153
TABLE 164 ISRAEL IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 153
TABLE 165 ISRAEL BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 153
TABLE 166 ISRAEL GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 154
TABLE 167 ISRAEL BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 154
TABLE 168 ISRAEL IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 154
TABLE 169 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 154
TABLE 170 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 155
TABLE 171 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 155
TABLE 172 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 155
TABLE 173 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 155
TABLE 174 REST OF MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 156

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SEGMENTATION 29
FIGURE 2 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: DATA TRIANGULATION 32
FIGURE 3 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: DROC ANALYSIS 33
FIGURE 4 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS 34
FIGURE 5 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 34
FIGURE 6 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 36
FIGURE 7 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DBMR MARKET POSITION GRID 37
FIGURE 8 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID 38
FIGURE 9 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 39
FIGURE 10 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SEGMENTATION 43
FIGURE 11 THE GROWING PREVALENCE OF LEUKEMIA CANCER IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN THE FORECAST PERIOD 44
FIGURE 12 THE INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN 2024 & 2031 44
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET 52
FIGURE 14 NUMBER OF PREVALENCE OF LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES) 54
FIGURE 15 FIVE YEARS PREVALENCE LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES) 54
FIGURE 16 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023 62
FIGURE 17 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2024-2031 (USD MILLION) 63
FIGURE 18 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2024-2031) 63
FIGURE 19 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 64
FIGURE 20 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2023 74
FIGURE 21 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2024-2031 (USD MILLION) 75
FIGURE 22 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2024-2031) 75
FIGURE 23 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 76
FIGURE 24 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2023 87
FIGURE 25 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2024-2031 (USD MILLION) 88
FIGURE 26 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2024-2031) 88
FIGURE 27 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 89
FIGURE 28 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2023 96
FIGURE 29 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2024-2031 (USD MILLION) 97
FIGURE 30 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2024-2031) 97
FIGURE 31 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE 98
FIGURE 32 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2023 103
FIGURE 33 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2024-2031 (USD MILLION) 104
FIGURE 34 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, CAGR (2024-2031) 104
FIGURE 35 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE 105
FIGURE 36 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2023 109
FIGURE 37 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2024-2031 (USD MILLION) 110
FIGURE 38 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, CAGR (2024-2031) 110
FIGURE 39 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 111
FIGURE 40 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023 117
FIGURE 41 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION) 118
FIGURE 42 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 118
FIGURE 43 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 119
FIGURE 44 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SNAPSHOT (2023) 123
FIGURE 45 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY SHARE 2023(%) 157